SearchDictionaryMobileLogin

Retroviridae Infections (Infection, Retrovirus)

Subscribe to Selected New Research on Retroviridae Infections
200  relevant articles (11 outcomes, 21 trials/studies) found for this Disease

Description: Virus diseases caused by the RETROVIRIDAE.

Also Known As:
Infection, Retrovirus; Infections, Retroviridae; Infections, Retrovirus; Infection, Retroviridae; Retroviridae Infection; Retrovirus Infection; Retrovirus Infections

Relationship Network

Disease Context: Research Results

-
Virus Diseases: 1376
-
RNA Virus Infections: 46
-
Retroviridae Infections: 200
*
Avian Sarcoma: 321
*
Murine Acquired Immunodeficiency Syndrome: 257
*
Deltaretrovirus Infections: 140
*
Avian Leukosis: 64
*
Lentivirus Infections: 47
*
Feline Leukemia: 41
*
Ovine Pulmonary Adenomatosis: 14

Related Diseases

1. Infection
2. Papilloma (Papillomatosis)
3. Acquired Immunodeficiency Syndrome (AIDS)
4. Retroviridae Infections (Infection, Retrovirus)
5. Contagious Ecthyma (Orf)

Experts

1. Dittmer, Ulf: 5 articles (04/2006 - 03/2002)
2. Schimmer, Simone: 3 articles (04/2006 - 07/2004)
3. Schepers, Koen: 3 articles (12/2004 - 03/2002)
4. Hasenkrug, Kim J: 2 articles (08/2004 - 03/2002)
5. Peterson, Karin E: 2 articles (08/2004 - 03/2002)
6. Messer, Ronald J: 2 articles (08/2004 - 03/2002)
7. Hasenkrug, K J: 2 articles (01/2001 - 01/2001)
8. Stromnes, I M: 2 articles (01/2001 - 01/2001)
9. Li, Xing: 1 article (10/2007)
10. Yeung, Darwin F: 1 article (10/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Retroviridae Infections:
1. cidofovir (Vistide)FDA Link
01/13/1994 - "Foremost among the acyclic nucleoside phosphonates currently pursued for their potential in the treatment of herpes and retrovirus infections are (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA). "
10/01/2003 - "Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections."
01/01/1997 - "The acyclic nucleoside phosphonates [HPMPC (cidofovir), PMEA (adefovir) and PMPA] have proved to the effective in vitro (cell culture systems) and in vivo (animal models, clinical studies) against a wide variety of DNA virus and retrovirus infections: i.e., HPMPC against herpesvirus (herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus types 6, 7, and 18), polyoma-, papilloma-, adeno-, and poxvirus (vaccinia virus, molluscum contagiosum virus) infections; PMEA against herpesvirus, hepadnavirus (human hepatitis B virus) and retrovirus (human immunodeficiency virus type 1 and 2, simian immunodeficiency virus, and feline immunodeficiency virus) infections; and PMPA against both hepadna- and retrovirus infections."
01/01/1990 - "Phosphonylmethoxyalkylpurines and -pyrimidines offer great promise for both topical and systemic treatment of various DNA virus and retrovirus infections: HPMPA for the treatment of adeno-, herpes- and poxvirus infections, HPMPC for the treatment of herpesvirus (in particular CMV) infections, and PMEA and PMEDAP for the treatment of retrovirus (i.e. "
10/01/2003 - "The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. "
Order ALL the reference details at left...
2. Phosphonic Acids (Phosphonates)IBA
3. adefovirIBA
07/01/1991 - "Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo."
01/13/1994 - "Foremost among the acyclic nucleoside phosphonates currently pursued for their potential in the treatment of herpes and retrovirus infections are (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA). "
10/01/2003 - "Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections."
01/01/1997 - "The acyclic nucleoside phosphonates [HPMPC (cidofovir), PMEA (adefovir) and PMPA] have proved to the effective in vitro (cell culture systems) and in vivo (animal models, clinical studies) against a wide variety of DNA virus and retrovirus infections: i.e., HPMPC against herpesvirus (herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus types 6, 7, and 18), polyoma-, papilloma-, adeno-, and poxvirus (vaccinia virus, molluscum contagiosum virus) infections; PMEA against herpesvirus, hepadnavirus (human hepatitis B virus) and retrovirus (human immunodeficiency virus type 1 and 2, simian immunodeficiency virus, and feline immunodeficiency virus) infections; and PMPA against both hepadna- and retrovirus infections."
10/01/2003 - "The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. "
Order ALL the reference details at left...
4. pinacolyl methylphosphonic acidIBA
01/01/1997 - "The acyclic nucleoside phosphonates [HPMPC (cidofovir), PMEA (adefovir) and PMPA] have proved to the effective in vitro (cell culture systems) and in vivo (animal models, clinical studies) against a wide variety of DNA virus and retrovirus infections: i.e., HPMPC against herpesvirus (herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus types 6, 7, and 18), polyoma-, papilloma-, adeno-, and poxvirus (vaccinia virus, molluscum contagiosum virus) infections; PMEA against herpesvirus, hepadnavirus (human hepatitis B virus) and retrovirus (human immunodeficiency virus type 1 and 2, simian immunodeficiency virus, and feline immunodeficiency virus) infections; and PMPA against both hepadna- and retrovirus infections."
10/01/2003 - "The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. "
06/01/2003 - "The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections. "
Order ALL the reference details at left...
5. tenofovirIBA
10/01/2003 - "Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections."
10/01/2003 - "The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. "
06/01/2003 - "The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections. "
Order ALL the reference details at left...
6. Carbon MonoxideIBA
7. tenofovir disoproxil (Viread)FDA Link
8. adefovir dipivoxil (Hepsera)FDA Link
9. DNA (Deoxyribonucleic Acid)IBA
10. VaccinesIBA

Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)
3. Transplants (Transplant)
4. Bioreactors
5. Institutionalization (Institutionalized Persons)

Best Treatments:
Research Summary Report
on Retroviridae Infections
*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 11 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>